Txcell S Awas A Biotechnology Company That Specialized In Personalized T Cell Immunotherapiesfocusing On Regulatory T Cellstregsto Treat Severe Autoimmune And Inflammatory Disordersas Well As Transplantation Related Issuesthe Company Developed Innovative Car Treg Therapies Aimed At Modulating Immune Responses For Conditions Like Multiple Sclerosis And Transplant Rejectiontxcell Utilized Patient Specific Tregs To Create Tailored Treatmentsemphasizing Precision Medicine In Immunology In 2018Txcell Was Acquired By Sangamo Therapeuticsintegrating Its Expertise In Tregs With Sangamoae S Gene Editing Capabilitiesthis Acquisition Aimed To Enhance The Development Of Car Treg Clinical Trialswith The First Trial Anticipated In 2019Txcell S Focus On Clinical Applications Positioned It As A Pioneer In Car Treg Developmentaddressing Significant Unmet Medical Needs In The Field Of Immunology
No conferences found for this company.
| Company Name | Txcell Sa |
| Country |
France
|
| Address | N/A |
| Telephone | N/A |
| N/A |
